LIGAND PHARMACEUTICALS INCORPORATED Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings
LIGAND PHARMACEUTICALS INCORPORATED (LGNYZ) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings of -$261.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 · last filed 2026-08-07
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2026-06-30 was -$43.00K, a 110.26% decline year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2026-03-31 was -$218.00K.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2025-12-31 was -$932.00K.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2025-09-30 was -$111.00K.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2025 was -$798.00K.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2024 was -$12.88M, a 5251.20% decline from fiscal 2023.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2023 was $250.00K.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2022 was -$274.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$43.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$261.00K 10-Q · filed 2026-08-07 | -$1.19M derived: sum of 3 quarters · filed 2026-08-07 | -$1.30M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2026-03-31 | -$218.00K 10-Q · filed 2026-05-08 | -$1.15M derived: sum of 2 quarters · filed 2026-05-08 | -$1.26M derived: sum of 3 quarters · filed 2026-05-08 | -$842.00K derived: sum of 4 quarters · filed 2026-05-08 | |
| 2025-12-31 | -$932.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$1.04M derived: sum of 2 quarters · filed 2026-02-27 | -$624.00K derived: sum of 3 quarters · filed 2026-02-27 | -$798.00K 10-K · filed 2026-02-27 | |
| 2025-09-30 | -$111.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $308.00K derived: sum of 2 quarters · filed 2025-11-07 | $134.00K 10-Q · filed 2025-11-07 | -$5.41M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2025-06-30 | $419.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $245.00K 10-Q · filed 2025-08-08 | -$5.30M derived: sum of 3 quarters · filed 2026-02-27 | -$29.56M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2025-03-31 | -$174.00K 10-Q · filed 2025-05-09 | -$5.71M derived: sum of 2 quarters · filed 2026-02-27 | -$29.98M derived: sum of 3 quarters · filed 2026-02-27 | -$13.25M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-12-31 | -$5.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$29.81M derived: sum of 2 quarters · filed 2026-02-27 | -$13.07M derived: sum of 3 quarters · filed 2026-02-27 | -$12.88M 10-K · filed 2026-02-27 | -$20.01M 10-K · filed 2025-02-28 |
| 2024-09-30 | -$24.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$7.53M derived: sum of 2 quarters · filed 2024-11-08 | -$7.34M 10-Q · filed 2024-11-08 | ||
| 2024-06-30 | $16.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $16.93M 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | $196.00K 10-Q · filed 2024-05-08 | ||||
| 2023-12-31 | $250.00K 10-K · filed 2025-02-28 | -$135.00K 10-K · filed 2024-02-29 | |||
| 2022-12-31 | -$274.00K 10-K · filed 2024-02-29 | ||||
| 2014-12-31 | $2.91M 10-K · filed 2014-12-01 | ||||
| 2013-12-31 | $713.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2014-12-12 | $4.31M derived: sum of 2 quarters · filed 2014-12-12 | $2.91M 10-K/A · filed 2014-12-12 | ||
| 2013-09-30 | $3.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $2.20M 10-Q · filed 2013-11-08 | |||
| 2013-06-30 | -$1.40M 10-Q · filed 2013-08-01 |